Glycolysis-related biomarker TCIRG1 participates in regulation of renal cell carcinoma progression and tumor immune microenvironment by affecting aerobic glycolysis and AKT/mTOR signaling pathway

• DOI: 10.1186/s12935-023-03019-0
• Publication Date: 2023-08-30T15:12:56Z
• Authors: Sichen Di; Min Gong; Jianmin Lv; Qiwei Yang; Ye Sun; Yijun Tian; Cheng Qian; Wenjin Chen; Wang Zhou; Keqin Dong; Xiaokai Shi; Yuning Wang; Hongru Wang; Jian Chu; Sishun Gan; Xiuwu Pan; Xingang Cui
• Keywords: Anaerobic glycolysis; CCL5; Tumor progression

Renal cell carcinoma (RCC) is a hypermetabolic disease. Abnormal up-regulation of glycolytic signaling promotes tumor growth, and metabolism closely related to immunotherapy renal cancer. The aim the present study was determine whether how glycolysis-related biomarker TCIRG1 affects aerobic glycolysis, microenvironment (TME) malignant progression clear (ccRCC).Based on Cancer Genome Atlas (TCGA, n = 533) gene set from MSigDB, we identified by bioinformatics analysis, analyzed its immunological properties in ccRCC observed it affected biological function using online databases such as TIMER 2.0, UALCAN, LinkedOmics vitro experiments.It found that expression TCIRG1, significantly increased tissue, high associated with poor overall survival (OS) short progression-free interval (PFI). In addition, highly correlated infiltration immune cells, especially CD4+T Th1, CD8+T cell, NK M1 macrophage, positively PDCD1, CTLA4 other immunoinhibitors, CCL5, CXCR3 chemokines chemokine receptors. More importantly, may regulate glycolysis via AKT/mTOR pathway, thereby affecting lines.Our results demonstrate tumor-promoting factor ccRCC, this finding provide new idea for treatment combination metabolic intervention immunotherapy.